1887

Abstract

The aim of this study was to assess the clinical and socio-demographic risk factors for primary antibacterial resistance. In total, 266 consecutive strains, from untreated symptomatic adult patients who answered a questionnaire, were evaluated. Strain susceptibility to amoxicillin, metronidazole, clarithromycin and tetracycline was tested by a breakpoint susceptibility test. Metronidazole resistance was found in fewer (17.0 %) peptic ulcer patients than in non-ulcer subjects (28.3 %, =0.037), as well as in fewer patients born in villages (12.7 %) than in those born in towns (27.6 %, =0.016). Clarithromycin resistance varied from 8.8 to 23.4 % (=0.009) within the hospital centres. The highest clarithromycin resistance rate was found in hospital centre A (23.4 %) compared to other centres (12.9 %, =0.041). The factors sex, age, symptom duration, non-steroidal anti-inflammatory drug use, diabetes, type of profession and educational level were not associated with resistance. Logistic regression revealed that the risk factors for metronidazole resistance were non-ulcer disease [odds ratio (OR) 1.95, 95 % confidence interval (95 % CI) 1.04–3.65] and a birthplace of a town (OR 2.64, 95 % CI 1.18–5.93). The hospital centre may be a risk factor (OR 2.07, 95 % CI 1.02–4.21) for clarithromycin resistance but further studies are required to verify this suggestion. In conclusion, the knowledge of the risk factors for resistance to antibacterials could facilitate the treatment choice for eradication.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.003855-0
2009-01-01
2019-11-22
Loading full text...

Full text loading...

/deliver/fulltext/jmm/58/1/94.html?itemId=/content/journal/jmm/10.1099/jmm.0.003855-0&mimeType=html&fmt=ahah

References

  1. Boyanova, L. ( 2007; ). Detection of Helicobacter pylori infection in symptomatic Bulgarian adults. Clin Microbiol Infect 13, 908–914.[CrossRef]
    [Google Scholar]
  2. Boyanova, L., Gergova, G., Nikolov, R., Davidkov, L., Kamburov, V., Jelev, C. & Mitov, I. ( 2008; ). Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis 60, 409–415.[CrossRef]
    [Google Scholar]
  3. Broutet, N., Tchamgoue, S., Pereira, E., Lamouliatte, H., Salamon, R. & Mégraud, F. ( 2003; ). Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 17, 99–109.[CrossRef]
    [Google Scholar]
  4. Buzás, G. M., Lotz, G. & Kiss, A. ( 2007; ). The epidemiology of clarithromycin resistance of Helicobacter pylori infection in Hungary. Orv Hetil 148, 1461–1467.[CrossRef]
    [Google Scholar]
  5. Chisholm, S. A., Teare, E. L., Davies, K. & Owen, R. J. ( 2007; ). Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000–2005). Euro Surveill 12, E3–E4.
    [Google Scholar]
  6. CLSI ( 2000; ). Performance Standards for Antimicrobial Susceptibility Testing, tenth informational supplement, approved standard M100–S10, M7. Wayne, PA: Clinical and Laboratory Standards Institute (formerly known as the National Committee for Clinical Laboratory Standards).
  7. Duck, W. M., Sobel, J., Pruckler, J. M., Song, Q., Swerdlow, D., Friedman, C., Sulka, A., Swaminathan, B., Taylor, T. & other authors ( 2004; ). Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 10, 1088–1094.[CrossRef]
    [Google Scholar]
  8. Elviss, N. C., Owen, R. J., Xerry, J., Walker, A. M. & Davies, K. ( 2004; ). Helicobacter pylori antibiotic resistance patterns and genotypes in adult dyspeptic patients from a regional population in North Wales. J Antimicrob Chemother 54, 435–440.[CrossRef]
    [Google Scholar]
  9. Elviss, N. C., Owen, R. J., Breathnach, A., Palmer, C. & Shetty, N. ( 2005; ). Helicobacter pylori antibiotic-resistance patterns and risk factors in adult dyspeptic patients from ethnically diverse populations in central and south London during 2000. J Med Microbiol 54, 567–574.[CrossRef]
    [Google Scholar]
  10. Ferrero, M., Ducons, J. A., Sicilia, B., Santolaria, S., Sierra, E. & Gomollon, F. ( 2000; ). Factors affecting the variation in antibiotic resistance of Helicobacter pylori over a 3-year period. Int J Antimicrob Agents 16, 245–248.[CrossRef]
    [Google Scholar]
  11. Gisbert, J. P., Marcos, S., Gisbert, J. L. & Pajares, J. M. ( 2001; ). Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol 13, 1303–1307.[CrossRef]
    [Google Scholar]
  12. Halitim, F., Vincent, P., Michaud, L., Kalach, N., Guimber, D., Boman, F., Turck, D. & Gottrand, F. ( 2006; ). High rate of Helicobacter pylori reinfection in children and adolescents. Helicobacter 11, 168–172.[CrossRef]
    [Google Scholar]
  13. Huang, J. Q., Zheng, G. F., Hunt, R. H., Wong, W. M., Lam, S. K., Karlberg, J. & Wong, B. C. ( 2005; ). Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. World J Gastroenterol 11, 2726–2732.[CrossRef]
    [Google Scholar]
  14. Katelaris, P. H., Nguyen, T. V., Robertson, G. J., Bradbury, R. & Ngu, M. C. ( 1998; ). Prevalence and demographic determinants of metronidazole resistance by Helicobacter pylori in a large cosmopolitan cohort of Australian dyspeptic patients. Aust N Z J Med 28, 633–638.[CrossRef]
    [Google Scholar]
  15. Kato, M., Yamaoka, Y., Kim, J. J., Reddy, R., Asaka, M., Kashima, K., Osato, M. S., El-Zaatari, F. A., Graham, D. Y. & Kwon, D. H. ( 2000; ). Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 44, 2214–2216.[CrossRef]
    [Google Scholar]
  16. Kawabata, H., Habu, Y., Tomioka, H., Kutsumi, H., Kobayashi, M., Oyasu, K., Hayakumo, T., Mizuno, S., Kiyota, K. & other authors ( 2003; ). Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 17, 259–264.[CrossRef]
    [Google Scholar]
  17. Koivisto, T. T., Rautelin, H. I., Voutilainen, M. E., Niemelä, S. E., Heikkinen, M., Sipponen, P. I. & Färkkilä, M. A. ( 2004; ). Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. Aliment Pharmacol Ther 19, 1009–1017.[CrossRef]
    [Google Scholar]
  18. Lui, S. Y., Yeoh, K. G. & Ho, B. ( 2003; ). Metronidazole-resistant Helicobacter pylori is more prevalent in patients with nonulcer dyspepsia than in peptic ulcer patients in a multiethnic Asian population. J Clin Microbiol 41, 5011–5014.[CrossRef]
    [Google Scholar]
  19. McMahon, B. J., Hennessy, T. W., Bensler, J. M., Bruden, D. L., Parkinson, A. J., Morris, J. M., Reasonover, A. L., Hurlburt, D. A., Bruce, M. G. & other authors ( 2003; ). The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 139, 463–469.[CrossRef]
    [Google Scholar]
  20. Megraud, F. ( 2004; ). H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53, 1374–1384.[CrossRef]
    [Google Scholar]
  21. Megraud, F. & Lehours, P. ( 2007; ). Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 20, 280–322.[CrossRef]
    [Google Scholar]
  22. Megraud, F., Lehn, N., Lind, T., Bayerdorffer, E., O'Morain, C., Spiller, R., Unge, P., van Zanten, S. V., Wrangstadh, M. & Burman, C. F. ( 1999; ). Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 43, 2747–2752.
    [Google Scholar]
  23. Meyer, J. M., Silliman, N. P., Wang, W., Siepman, N. Y., Sugg, J. E., Morris, D., Zhang, J., Bhattacharyya, H., King, E. C. & Hopkins, R. J. ( 2002; ). Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med 136, 13–24.[CrossRef]
    [Google Scholar]
  24. Ojetti, V., Migneco, A., Silveri, N. G., Ghirlanda, G., Gasbarrini, G. & Gasbarrini, A. ( 2005; ). The role of H. pylori infection in diabetes. Curr Diabetes Rev 1, 343–347.[CrossRef]
    [Google Scholar]
  25. Osato, M. S., Reddy, R., Reddy, S. G., Penland, R. L., Malaty, H. M. & Graham, D. Y. ( 2001; ). Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 161, 1217–1220.[CrossRef]
    [Google Scholar]
  26. Parsons, H. K., Carter, M. J., Sanders, D. S., Winstanley, T. & Lobo, A. J. ( 2001; ). Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther 15, 1473–1478.[CrossRef]
    [Google Scholar]
  27. Pilotto, A., Rassu, M., Leandro, G., Franceschi, M. & Di Mario, F., Interdisciplinary Group for the Study of Ulcer ( 2000; ). Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. . Dig Liver Dis 32, 763–768.[CrossRef]
    [Google Scholar]
  28. Sargýn, M., Uygur-Bayramicli, O., Sargýn, H., Orbay, E., Yavuzer, D. & Yayla, A. ( 2003; ). Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. World J Gastroenterol 9, 1126–1128.
    [Google Scholar]
  29. Seow, J. & Chew, F. T. ( 2004; ). Risk factors for Helicobacter pylori resistance. Ann Intern Med 140, 931 [CrossRef]
    [Google Scholar]
  30. Thyagarajan, S. P., Ray, P., Das, B. K., Ayyagari, A., Khan, A. A., Dharmalingam, S., Rao, U. A., Rajasambandam, P., Ramathilagam, B. & other authors ( 2003; ). Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: multicentric study. J Gastroenterol Hepatol 18, 1373–1378.[CrossRef]
    [Google Scholar]
  31. Toracchio, S. & Marzio, L. ( 2003; ). Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998–2002. Dig Liver Dis 35, 541–545.[CrossRef]
    [Google Scholar]
  32. Van Doorn, L. J., Schneeberger, P. M., Nouhan, N., Plaisier, A. P., Quint, W. G. & de Boer, W. A. ( 2000; ). Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut 46, 321–326.[CrossRef]
    [Google Scholar]
  33. Wang, W. H., Wong, W. M., Dailidiene, D., Berg, D. E., Gu, Q., Lai, K. C., Lam, S. K. & Wong, B. C. ( 2003; ). Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut 52, 490–495.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.003855-0
Loading
/content/journal/jmm/10.1099/jmm.0.003855-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error